Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.
Hanna Jean Khoury
No relevant relationships to disclose
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Dong-Wook Kim
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis; Wyeth
Research Funding - Bristol-Myers Squibb; Novartis; Wyeth
Javier Pinilla-Ibarz
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Research Funding - ARIAD
Philipp D. Le Coutre
Honoraria - Bristol-Myers Squibb; Novartis
Ronald Paquette
Honoraria - ARIAD
Charles Chuah
Honoraria - Bristol-Myers Squibb; Novartis
Franck E. Nicolini
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - Novartis
Jane Apperley
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Moshe Talpaz
Consultant or Advisory Role - ARIAD
Research Funding - ARIAD
John F. DiPersio
No relevant relationships to disclose
Daniel J. DeAngelo
Consultant or Advisory Role - ARIAD
Elisabetta Abruzzese
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Delphine Rea
Honoraria - Bristol-Myers Squibb; Novartis; Teva
Michele Baccarani
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Martin C. Müller
No relevant relationships to disclose
Carlo Gambacorti-Passerini
No relevant relationships to disclose
Stephanie Lustgarten
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Kumiko Yanase
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Hagop M. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer